← ANALYST RATINGS · TIPRANKS
Disc Medicine (IRON): analyst forecast and price target
Analyst consensus
Strong Buy11 Buy0 Hold0 Sell
Ratings of 11 analysts in the last 3 months · top analysts only12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $102, the highest $125, the lowest $86.00. The average is +79.8% from the last price of $56.84.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $56.00 → $57.00+1.8% | Hold | +0.3% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $56.00 → $57.00+1.8% | Hold | +0.3% | Reiterated | 16.10.26on TipRanks 19:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $57.00 → $58.00+1.8% | Hold | +2.0% | Reiterated | 16.10.26on TipRanks 19:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $58.00 → $59.00+1.7% | Hold | +3.8% | Reiterated | 16.10.26on TipRanks 10:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $57.00 → $58.00+1.8% | Hold | +2.0% | Reiterated | 16.10.26on TipRanks 10:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $54.00 → $55.00+1.9% | Hold | −3.2% | Reiterated | 16.10.26on TipRanks 10:06 | — | |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $120 | Buy | +111.1% | Reiterated | 13.10.26on TipRanks 06:26 | −6.4%next day −0.4% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | — | Buy | — | Reiterated | 21.09.26on TipRanks 07:55 | −3.0%next day 0.0% · 5 days −4.2% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $79.00 → $86.00+8.9% | Buy | +51.3% | Assigned | 16.09.26on TipRanks 06:35 | +2.3%next day −0.2% · 5 days −5.7% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $100 | Buy | +75.9% | Reiterated | 10.09.26on TipRanks Sep 11 08:35 | −2.5%next day −6.4% · 5 days −7.3% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $100 | Buy | +75.9% | Reiterated | 10.09.26on TipRanks 07:50 | −2.5%next day −6.4% · 5 days −7.3% | ↗ |
| Rami Katkhuda★★★★★★★★★★#297 · hits 55% · avg +31.7% | LifeSci Capital | $100 | Buy | +75.9% | Reiterated | 10.09.26on TipRanks 07:35 | −2.5%next day −6.4% · 5 days −7.3% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $125 | Buy | +119.9% | Reiterated | 31.08.26on TipRanks Sep 1 07:35 | −1.4%next day +0.7% · 5 days −2.2% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $85.00 → $90.00+5.9% | Buy | +58.3% | Assigned | 17.08.26on TipRanks 08:55 | +2.0%next day +0.9% · 5 days +2.3% | ↗ |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $88.00 | Buy | +54.8% | Reiterated | 11.08.26on TipRanks 09:55 | +4.1%next day −1.0% · 5 days −0.8% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $111 | Buy | +95.3% | Reiterated | 31.07.26on TipRanks 11:18 | −3.5%next day −2.3% · 5 days −2.9% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | — | Buy | — | Reiterated | 30.07.26on TipRanks 13:45 | +5.8%next day −3.5% · 5 days −5.9% | ↗ |
| Martin Auster★★★★★★★★★★#1128 · hits 51% · avg +16.1% | Raymond James | $78.06 → $117+49.9% | Buy | +105.8% | Reiterated | 13.01.26on TipRanks 10:24 | −4.3%next day +2.7% · 5 days +0.5% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $154 | Buy | +170.9% | Reiterated | 19.12.25on TipRanks 15:15 | −12.4%next day −1.2% · 5 days −3.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Disc Medicine
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $102 at a price of $65.46 (+56.2%); now: $102 at $56.84 (+79.8%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 5 | 5 | 6 |
| Buy | 9 | 18 | 23 | 21 | 15 | 10 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.63 (from $-1.93 to $-1.28). Last quarter: $-1.54.
Best top-analyst consensus in the sector · Healthcare
About Disc Medicine
- CEO: John D. Quisel
- Employees: 165
- 321 Arsenal Street, Watertown, MA, 02472, US
- www.discmedicine.com
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Data from the stock’s TipRanks forecast page, read 60 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗